Bod Australia achieved record total attributable sales of A$3.33m in Q2 FY21, a 52% increase on the previous quarter and a 144% rise on Q2 FY20.
Sales for the period were supported by a number of purchase orders from exclusive global partner Health and Happiness Group for the launch of CBD and hemp products in key markets including the Netherlands, France, Italy and the UK as well as increased prescription volumes of medicinal cannabis product MediCabilis.
Bod expects sales growth to continue during 2021 as the company enters additional markets and achieves growth in medicinal cannabis sales in Australia and the UK.
Bod CEO Jo Patterson said: “The progress achieved over the last quarter is a great result for Bod. The company has considerably broadened its international footprint, with new market entries into the Netherlands, France and Italy, [and] extended its product ranges in the UK.
“Further, we have increased sales of our medicinal cannabis products in Australia and are now benefiting from this growth. Demand for our medicinal cannabis, CBD and hemp products continues to escalate and we expect binding purchase orders to increase during the current period and the remainder of FY21.”